CicloMed LLC, a developmental-stage pharmaceutical company with a collaborative team of experts in drug development and cancer treatment, is developing a novel drug candidate known as Ciclopirox Prodrug for potential treatment of bladder cancer. Our paradigm-changing approach springs from a productive public-private partnership with The University of Kansas Cancer Center. Scientists at KU discovered Ciclopirox Prodrug and demonstrated its potential in preclinical models as an anticancer agent. Ciclopirox Prodrug for Injection was licensed to CicloMed in 2015. Our team is collaborating with experts across the country to develop this novel drug for the treatment of muscle invasive and non-muscle invasive bladder cancer.